TP53 and non-small cell lung carcinoma: Further, we showed that in NSCLC cells metformin enhances the anti-tumor activity of other AMPK-activating agents such as salicylate in both p53 null and LKB1 null cells, through a mechanism that involves AMPK β1 subunit and DNL [114] (Table 1).